PORTFOLIO NEWS Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders February 8, 2024 Read More » Tenaya Therapeutics Announces Pricing of Underwritten Offering February 8, 2024 Read More » Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader February 1, 2024 Read More » Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer February 1, 2024 Read More » Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases January 29, 2024 Read More » Carmot Therapeutics Announces Completion of Acquisition by Roche January 29, 2024 Read More » Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies January 23, 2024 Read More » ORIC Pharmaceuticals Announces $125 Million Private Placement Financing January 22, 2024 Read More » Tr1X Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases January 17, 2024 Read More » Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL January 16, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders February 8, 2024 Read More »
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader February 1, 2024 Read More »
Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer February 1, 2024 Read More »
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases January 29, 2024 Read More »
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies January 23, 2024 Read More »
Tr1X Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases January 17, 2024 Read More »
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL January 16, 2024 Read More »
